Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNP-CTNNB1
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
LNP-CTNNB1 is a lipid nanoparticle (LNP) formulation encapsulating siRNA that specifically targets the CTNNB1 gene, which encodes β-catenin[1][2][3][4]. This agent is designed for RNAi-mediated gene knockdown in hepatocellular carcinoma (HCC) models bearing CTNNB1 mutations. Mechanistically, it suppresses β-catenin signaling, resulting in reduced expression of key Wnt/β-catenin target genes (such as Glul and Ccnd1), decreased tumor cell proliferation, and increased tumor cell death, reprogramming both tumor cells and the immune microenvironment to enhance antitumor response[1][2][3][4]. Preclinical data demonstrates efficacy as a monotherapy and in combination with immune checkpoint inhibitors (ICI), extending survival and restoring antitumor immune function with durable tumor suppression in models of CTNNB1-mutated HCC[1][2][3][4]. The molecule is designed for systemic administration (intravenous) in preclinical models[1][4]. Developer details are not explicitly stated in the sources.
- Brand names
- LNP-CTNNB1LNP-CTNNB-1LNP-CTNNB 1
- Other names
- LNP-CTNNB1LNP-CTNNB-1LNP-CTNNB 1
02
Targets
CTNNB1 (Beta-catenin)
Beyond the preview
Go deeper on LNP-CTNNB1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNP-CTNNB1.